Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine and DOR/3TC/TDF in Pediatric Participants With HIV-1
NCT04375800Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Feb 2021; status: recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04375800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375800.